Mark H Duncan
Overview
Explore the profile of Mark H Duncan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fortney J, Ratzliff A, Blanchard B, Ferro L, Rouvere J, Chase E, et al.
Contemp Clin Trials
. 2024 Sep;
146():107700.
PMID: 39322115
Background: The gold-standard treatment for opioid use disorder (OUD) is medication for OUD (MOUD). However, less than a quarter of people with OUD initiate MOUD. Expanding the Collaborative Care Model...
2.
Alawadhi Y, Shinagawa E, Taylor E, Jackson C, Fragasso A, Howard M, et al.
Int J Drug Policy
. 2024 Jun;
129:104448.
PMID: 38905941
Background: Two, randomized controlled trials found harm-reduction treatment for AUD (HaRT-A) improves alcohol outcomes for adults experiencing homelessness. HaRT-A, which neither requires nor precludes abstinence, entails tracking alcohol-related harm, harm-reduction...
3.
Ramaraj A, Franz N, Bhat A, Adachi J, Quiray J, Bespalova N, et al.
Acad Psychiatry
. 2023 Dec;
48(3):249-253.
PMID: 38085422
Objective: Perinatal mental health and substance use disorders (PMHSUD) often go unrecognized and untreated. This study examined the use of the Project ECHO model to teach obstetric, primary care, and...
4.
Fortney J, Ratzliff A, Blanchard B, Johnson M, Ferro L, Austin E, et al.
Ann Intern Med
. 2023 Oct;
176(10):1431-1433.
PMID: 37844317
No abstract available.
5.
Hallgren K, Duncan M, Iles-Shih M, Cohn E, McCabe C, Chang Y, et al.
JMIR Form Res
. 2023 Jul;
7:e47516.
PMID: 37410529
Background: In the United States, methamphetamine-related overdoses have tripled from 2015 to 2020 and continue to rise. However, efficacious treatments such as contingency management (CM) are often unavailable in health...
6.
Vutien P, Kim N, Merrill J, Duncan M, Ioannou G, Collins S
J Addict Med
. 2023 Jun;
17(3):363-366.
PMID: 37267194
Objectives: The use of extended-release naltrexone (XR-NTX) as treatment for alcohol use disorder (AUD) has been limited by a prior black box warning for hepatotoxicity. We performed a secondary analysis...
7.
Duncan M, Erickson J, Chang D, Toor R, Ratzliff A
Psychiatr Clin North Am
. 2022 Feb;
45(1):71-80.
PMID: 35219443
Integrated behavioral care, and in particular, the collaborative care model, has been working to improve access and treatment for people with mental health disorders. Integrated care allows for adaptable, scalable,...
8.
Ratzliff A, Toor R, Erickson J, Bauer A, Duncan M, Chang D, et al.
J Acad Consult Liaison Psychiatry
. 2022 Feb;
63(3):280-289.
PMID: 35123126
Background: Integrated care is a common approach to leverage scarce psychiatric resources to deliver mental health care in primary care settings. Objective: Describe a formal clinical fellowship devoted to professional...
9.
Fentress T, Wald S, Brah A, Leemon G, Reyes R, Alkhamees F, et al.
Exp Clin Psychopharmacol
. 2021 Jul;
29(3):261-271.
PMID: 34264737
Two recent randomized controlled efficacy trials showed that harm-reduction treatment for alcohol use disorder (AUD)-or patient-driven treatment that does not require abstinence and instead supports decreased alcohol-related harm and improved...
10.
Collins S, Duncan M, Saxon A, Taylor E, Mayberry N, Merrill J, et al.
Lancet Psychiatry
. 2021 Mar;
8(4):287-300.
PMID: 33713622
Background: The rate of alcohol-related mortality in people experiencing homelessness and alcohol use disorder is high and necessitates accessible and effective treatment for alcohol use disorder. However, typical abstinence-based treatments...